Stock Research Monitor: ATNM, AMRN, and APRI
LONDON, UK / ACCESSWIRE / June 4, 2018 / If you want a free Stock Review on AXON sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com scans Actinium Pharmaceuticals Inc. (NYSE AMER: ATNM), Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences Inc. (NASDAQ: APRI), and Axovant Sciences Ltd (NASDAQ: AXON). Companies in the Biotechnology industry harness biological processes to create technologies and products for a wide variety of challenges - from expanding crop sizes to treating disease. All you have to do is sign up today for this free limited time offer by clicking the link below.
New York-based Actinium Pharmaceuticals Inc.'s stock finished last Friday's session 3.92% higher at $0.40. A total volume of 2.38 million shares was traded, which was above their three months average volume of 892,040 shares. The Company's shares have advanced 13.15% in the past month. The stock is trading above its 50-day moving average by 8.12%. Additionally, shares of Actinium Pharma, which develops targeted therapies for patients with cancers lacking effective treatment options, have a Relative Strength Index (RSI) of 65.29. Get the full research report on ATNM for free by clicking below at:
On Friday, shares in Dublin, Ireland-based Amarin Corp. PLC ended the session 1.51% higher at $3.36. The stock recorded a trading volume of 1.81 million shares. The Company's shares have gained 16.26% in the last month and 12.00% over the past year. The stock is trading 10.03% above its 50-day moving average. Moreover, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have an RSI of 60.73.
On May 23rd, 2018, Amarin announced that John F. Thero, President and CEO, is scheduled to present a general company update at the Jefferies Global Healthcare Conference on June 07th, 2018, at 8:00 a.m. EDT in New York City. A live audio webcast of the presentation will be available on the Company's website. Access the free research report on AMRN now by signing up at:
San Diego, California headquartered Apricus Biosciences Inc.'s shares gained slightly by 0.57%, closing the session at $0.28 with a total trading volume of 255,314 shares. The stock has gained 6.32% in the last month. The stock is trading 19.05% below their 50-day moving average. Additionally, shares of Apricus Biosciences, which focuses on the development of product candidates in the areas of urology and rheumatology, have an RSI of 42.71. Are you already registered with Wall St. Equities? Do so now for free, and get the report on APRI at:
Last Friday at the close, shares in London, the UK-based Axovant Sciences Ltd recorded a trading volume of 7.15 million shares, which was above their three months average volume of 840,220 shares. The stock ended the session 13.61% higher at $1.92. The Company's shares have advanced 69.91% in the past month and 24.68% over the previous three months. The stock is trading above its 50-day moving average by 55.95%. Furthermore, shares of Axovant Sciences, which engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the US and Europe, have an RSI of 74.90.
On May 31st, 2018, Axovant Sciences announced that Pavan Cheruvu, M.D., CEO, will present a corporate overview at the Jefferies 2018 Global Healthcare Conference on June 07th, 2018 at 9:00 a.m. ET, and at the JMP Securities Life Science Conference on June 21st, 2018 at 9:00 a.m. ET. A live webcast for each conference will be available under the Investors section of the Company's website. Aspiring Member, please take a moment to register below for your free research report on AXON at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities